Cosmo NVCMOPF +0.13%82 Days Inventory is 73.60 as of Dec. 2025, which is 62% below its 10-year median of 193.88. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.89 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 917 Drug Manufacturers companies, Cosmo NV ranks better than 85.71% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Cosmo NV's Average Total Inventories for the
six
months ended in Dec. 2025 was $13.2 Mil. Cosmo NV's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $32.8 Mil.
Hence, Cosmo NV's Days Inventory for the
six
months ended in Dec. 2025 was 73.60.
The historical rank and industry rank for Cosmo NV's Days Inventory or its related term are showing as below:
CMOPF'
s Days Inventory Range Over the Past 10 Years
Min: 63.13 Med: 193.88 Max: 250.76
Current: 82.36
During the past 13 years, Cosmo NV's highest Days Inventory was 250.76. The lowest was 63.13. And the median was 193.88.
CMOPF's Days Inventory is ranked better than 85.71% of 917
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs CMOPF: 82.36
Cosmo NV's Days Inventory
declined
from Dec. 2024 (114.22) to Dec. 2025 (73.60).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Cosmo NV's Inventory Turnover for the
six
months ended in Dec. 2025 was 2.48.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cosmo NV's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.22.
Cosmo NV (OTCPK:CMOPF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Cosmo NV's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cosmo NV's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Cosmo NV Days Inventory Related Terms
Cosmo NV Days Inventory Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Days Inventory distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a Days Inventory of 73.60 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cosmo NV and its competitors. This is 62% below median its historical median of 193.88. Over the past decade, Cosmo NV's Days Inventory has ranged from 63.13 to 250.76. According to the industry distribution chart, Cosmo NV ranks #131 out of 917 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is Cosmo NV's Days Inventory too high?
Cosmo NV's current Days Inventory of 73.60 is 62% below median its 10-year median of 193.88. Over the past 10 years, this metric has ranged from a low of 63.13 to a high of 250.76. The Drug Manufacturers industry median Days Inventory is 164.48. Cosmo NV's value of 73.60 is 55.3% below this industry median. Based on the distribution chart, Cosmo NV ranks #131 out of 917 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #131 out of 917 companies for Days Inventory. This places Cosmo NV in the top 14% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.48. Cosmo NV's value of 73.60 is 55.3% below this benchmark. Historically, Cosmo NV's own Days Inventory has ranged from 63.13 to 250.76 over the past decade. While the company's 10-year median is 193.88 vs. the industry median of 164.48, Cosmo NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Days Inventory of 73.60 is 55.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Days Inventory is 73.60, which is 62% below median its own 10-year median of 193.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.89, compared to a current price of $83.00 — trading 51.2% above its estimated fair value. The current Days Inventory is 73.60, which is 62% below median its 10-year median of 193.88 and 55.3% below the Drug Manufacturers industry median of 164.48. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Days Inventory is 73.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $83.00 is trading 51.2% above its estimated GF Value™ of $54.89.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Days Inventory: 73.60 (62% below median its 10-year median of 193.88)
GF Value™: $54.89 vs. price of $83.00 (51.2% above fair value)
Industry Position: 55.3% below the Drug Manufacturers median (#131 of 917)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
